Sunrise Announces Landmark Results from the SUNSAS Trial, the Largest Randomized Controlled Study of an At-Home Sleep Apnea Diagnostic Pathway Compared with PSG
Sunrise Group, a pioneer in medical device innovation and sleep care, today announced results from the SUNSAS clinical study, now published in The Lancet Regional Health – Europe, a leading international medical journal. Supported by the French Ministry of Health through the Forfait Innovation program, this study is the largest randomized controlled trial to date evaluating an at-home diagnostic pathway for obstructive sleep apnea (OSA) compared with gold-standard polysomnography (PSG).
New Study Shows Sunrise’s AI-Powered Measure of Respiratory Effort, REMOV, Better Reflects OSA Symptoms Than Traditional PSG Metrics
Sunrise Group, a pioneer in medical device innovation and sleep care, today announced a new peer-reviewed study in Nature Communications Medicine. Sunrise developed the only home sleep test with respiratory effort measurement that has been validated against esophageal pressure, the reference standard. The study reveals that REMOV, the Sunrise-specific marker of respiratory effort burden in obstructive sleep apnea (OSA), outperforms traditional polysomnography (PSG) metrics in predicting patient-reported symptoms.
Sunrise Group Raises $29 Million to Expand Dreem Health and Build the Largest U.S. Sleep Clinic
Sunrise Group, a leader in sleep health technology, today announced a $29 million funding round to expand Dreem Health, its digital sleep clinic, across all 50 states. The round was led by Eurazeo, with participation from Amazon’s Alexa Fund, WE International, Kurma Partners, Vives Fund, Majycc (an UI Investissement fund), Namur Invest, Seventure Partners, Investsud, Sambrinvest, Noshaq, IMBC and Invest.BW.
